''N''-Methyl-PPPA, or ''N''-methyl-3-phenoxy-3-phenylpropan-1-amine, is a
serotonin-norepinephrine reuptake inhibitor (SNRI) which was developed by
Eli Lilly
Eli Lilly (July 8, 1838 – June 6, 1898) was an American soldier, pharmacist, chemist, and businessman who founded the Eli Lilly and Company pharmaceutical corporation. Lilly enlisted in the Union Army during the American Civil War and ...
from
diphenhydramine
Diphenhydramine (DPH) is an antihistamine and sedative mainly used to treat allergies, insomnia, and symptoms of the common cold. It is also less commonly used for tremor in parkinsonism, and nausea. It is taken by mouth, injected into ...
in the early 1970s while in search of new
antidepressants, but was never marketed.
It is closely related structurally to
fluoxetine,
atomoxetine
Atomoxetine, sold under the brand name Strattera, among others, is a medication used to treat attention deficit hyperactivity disorder (ADHD). It may be used alone or along with psychostimulants. It is also used as a cognitive enhancer to impro ...
, and
nisoxetine.
See also
*
3-Phenoxy-3-phenylpropan-1-amine (PPPA)
*
Development and discovery of SSRI drugs Selective serotonin reuptake inhibitors, or serotonin-specific re-uptake inhibitor (SSRIs), are a class of chemical compounds that have contributed to the major advances as antidepressants where they have revolutionised the treatment of depression ...
*
Aryloxypropanamine scaffold
References
Experimental antidepressants
Drugs developed by Eli Lilly and Company
Serotonin–norepinephrine reuptake inhibitors
{{nervous-system-drug-stub